Kevin P.
- Country
- Belgium
- Department
- Medical Oncology
Research Overview
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- Efficacy and Safety of Giredestrant vs. Fulvestrant with CDK4/6 Inhibitor in ER+ HER2- Advanced Breast Cancer Resistant to Endocrine Therapy
- Evaluation of Trastuzumab Deruxtecan in Unresectable/Metastatic HER2-low or HER2 IHC0 Breast Cancer: A Multicenter, Open-label Study
Data & Insights
Has run more than one trial at 254 of 490 partner sites.
Specializations
Triple-Negative Breast Cancer
Specializes in investigating novel therapeutic approaches for triple-negative breast cancer (TNBC), particularly focusing on androgen receptor-positive TNBC and advanced metastatic cases. The investigator studies innovative combination therapies including antiandrogens and targeted treatments.
- Locally advanced inoperable TNBC
- Metastatic TNBC treatment
- Neoadjuvant therapy approaches
Hormone Receptor-Positive Breast Cancer
Conducts research in hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular emphasis on advanced and metastatic disease states. Explores treatment options for patients who have progressed after endocrine therapy.
- Advanced HR+ breast cancer
- Endocrine therapy resistance
- Novel therapeutic combinations
Targeted Therapies
Focuses on evaluating innovative targeted therapies including antibody-drug conjugates and immunotherapy approaches. Investigates treatment strategies for various breast cancer subtypes, particularly in advanced disease settings.
- Immunotherapy applications
- HER2-low breast cancer
- Personalized treatment approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.